Score Overview
Explore the 2021 public Archive ranking →
Where Genmab AS has ranked, year by year
Not enough ranking history to display a chart
This chart needs at least two years of available HDB Score rankings on 30 years of fundamentals. GMAB does not have enough ranked years in the public Archive through 2021.
More recent Archive years are available with Membership. Coverage varies by company and measure.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-09-29 | $ 35.57 | — |
1 Year2025-09-29 | $ 29.33 | 21.28% |
5 Years2021-09-29 | $ 42.34 | -15.99% |
10 Years2016-09-29 | $ 16.80 | 111.75% |
All Time2009-06-01 | $ 3.77 | 9x |
| Period | Last Price2026-09-29 | 1 Year2025-09-29 | 5 Years2021-09-29 | 10 Years2016-09-29 | All Time2009-06-01 |
|---|---|---|---|---|---|
| Price | $ 35.57 | $ 29.33 | $ 42.34 | $ 16.80 | $ 3.77 |
| Return | — | 21.28% | -15.99% | 111.75% | 9x |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
Reported in DKK
| Year | |||
|---|---|---|---|
| TTM | kr 4.13B | kr 788M | kr 1.50B |
| 2025 | kr 3.72B | kr 963M | kr 1.71B |
| 2024 | kr 21.52B | kr 7.84B | kr 21.10B |
| 2023 | kr 16.47B | kr 4.35B | kr 28.13B |
| 2022 | kr 14.50B | kr 5.45B | kr 22.32B |
| 2021 | kr 8.41B | kr 2.95B | kr 19.33B |
| 2020 | kr 10.11B | kr 4.75B | kr 16.07B |
| 2019 | kr 5.36B | kr 2.16B | kr 10.97B |
| 2018 | kr 3.02B | kr 1.47B | kr 6.10B |
| 2017 | kr 2.36B | kr 1.10B | kr 5.42B |
| 2016 | kr 1.81B | kr 1.18B | kr 3.92B |
| 2015 | kr 1.13B | kr 763M | kr 3.49B |
| 2014 | kr 850M | kr 301M | kr 2.66B |
| 2013 | kr 663M | kr 112M | kr 1.55B |
| 2012 | kr 484M | -kr 487M | kr 1.50B |
| 2011 | kr 350M | -kr 596M | kr 1.10B |
| 2010 | kr 582M | -kr 321M | kr 1.64B |
| IPO2009 | kr 586M | -kr 1.01B | kr 1.27B |
Genmab AS fundamental performance
Between 2020 and 2025, revenue declined from kr 10.11B to kr 3.72B and net income declined from kr 4.75B to kr 963M. Revenue increased in 4 of those 5 years; net income in 2.
Across Genmab AS's full reported history, from 2009 to 2025, revenue grew from kr 586M to kr 3.72B and net income went from -kr 1.01B to kr 963M. Revenue increased in 76% of the years measured; net income in 65%.
Genmab AS currently holds a 5-year HDB Score of 4.4 out of 10. How the HDB Score is calculated.
Membership
Explore GMAB with current data
The public Archive runs through 2021. Membership adds recent and current rankings.
- Recent and current rankings across 3,814 companies
- Compare companies with the latest data
- Track your research shortlist in a portfolio
